New drug combo aims to slow rapid aging in kids
NCT ID NCT02579044
First seen Apr 11, 2026 · Last updated May 13, 2026 · Updated 4 times
Summary
This study tests adding everolimus to the standard drug lonafarnib for children with progeria, a rare condition that causes rapid aging. The goal is to find the safest dose and see if the combination improves weight gain and blood vessel health. About 80 participants will take part at Boston Children's Hospital.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGERIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.